Holen Sie sich die Stockscreener-App
0.641
7.21%
-0.0498
Handel nachbörslich:
.67
0.029
+4.52%
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Bitget
AIM ImmunoTech (AIM) Projects $1.8M from Rights Offering - GuruFocus
Aim Immunotech Announces Expiration And Preliminary Results Of Its Rights Offering For Aggregate Gross Proceeds Of $1.8 Million - TradingView
AIM ImmunoTech raises $1.8M with $1,000 preferred stock and warrant bundles - Stock Titan
AIM ImmunoTech Signs Agreement for Planning of a Proposed - GlobeNewswire
AIM Collaborates with Thermo Fisher for Phase 3 Trial of Amplige - GuruFocus
AIM ImmunoTech Inc. has signed an agreement to plan a proposed Phase III clinical trial of its core candidate drug Ampligen for the treatment of advanced pancreatic cancer. - Bitget
Experimental pancreatic cancer drug Ampligen moves toward Phase 3 test - Stock Titan
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer - Sahm
AIM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AIM ImmunoTech (AIM) Updates Rights Offering Terms - GuruFocus
Investors get $1,000 AIM unit with 2,000 warrants — but clock is ticking - Stock Titan
AIM ImmunoTech (NYSE American: AIM) offers 12,000 Units and 24M warrants - Stock Titan
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering - Sahm
AIM Should I Buy - Intellectia AI
AIM ImmunoTech (AIM) Extends Rights Offering Subscription Period - GuruFocus
AIM ImmunoTech Inc. recently announced that it will extend the exercise period for shareholder subscription rights in its previously announced stock offering plan. - Bitget
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 - The Manila Times
Aim Immunotech Announces Extension Of Subscription Period - TradingView
AIM cancer-drug investors get new March 3 deadline, use-it-or-lose-it rights - Stock Titan
AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi - Indian Pharma Post
AIM ImmunoTech (AIM) Reports Progress in Pancreatic Cancer Study - GuruFocus
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer - Bitget
AIM ImmunoTech Announces Planned Milestones in the Ongoing - GlobeNewswire
New pancreatic cancer trial pairs AIM drug with AstraZeneca's Imfinzi - Stock Titan
AIM ImmunoTech at Virtual Investor Closing Bell: Strategic Focus on Pancreatic Cancer By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
AIM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Merger Talk: Will AIM ImmunoTech Inc. stock outperform global peersEarnings Beat & Verified Chart Pattern Trade Signals - mfd.ru
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering - The Manila Times
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - The Manila Times
Pancreatic cancer drug strategy: AIM ImmunoTech CEO in Feb. 19 live webcast - Stock Titan
AIM ImmunoTech at Corporate Connect: Ampligen’s Role in Pancreatic Cancer - Investing.com Canada
AIM: Ampligen demonstrates strong survival and quality of life benefits in late-stage pancreatic cancer - TradingView
AIM ImmunoTech launches rights offering to raise $12 million - Intellectia AI
AIM ImmunoTech Launches Rights Offering for Common Stock Holders - GuruFocus
Aim Immunotech Announces Commencement Of Rights Offering - TradingView
AIM ImmunoTech Announces Commencement of Rights Offering - GlobeNewswire
Cancer drug developer AIM ImmunoTech seeks $12M from shareholders - Stock Titan
ImmunoTech (AIM) updates S-1 with exhibits-only Amendment No. 3 - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
AIM ImmunoTech to Participate in Corporate Connect Webinar - Intellectia AI
AIM ImmunoTech to Participate in the Corporate Connect - GlobeNewswire
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - 富途牛牛
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted ... - Herald and News
AIM ImmunoTech Eyes $12M Funding Boost with Rights Offering - timothysykes.com
AIM ImmunoTech Inc. (AIM) stock: surges as pancreatic cancer trial shows survival breakthrough - parameter.io
AIM ImmunoTech reports year-end positive phase 2 interim progress for Ampligen® (rintatolimod) plus AstraZeneca's Imfinzi® (durvalumab) in pancreatic cancer - marketscreener.com
AIM ImmunoTech reports data in year-end update from Phase 2 trial of Ampligen - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
AIM ImmunoTech (AIM) Announces Positive Phase 2 Trial Results fo - GuruFocus
AIM ImmunoTech’s $12M Rights Offering: Implications and Prospects - StocksToTrade
Why Is AIM ImmunoTech Stock Up Today? - TipRanks
AIM ImmunoTech Rights Offering Targets $12 Million Boost - timothysykes.com
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial | AIM Stock News - Longbridge
AIM ImmunoTech Provides Interim DURIPANC Clinical Progress Update - TipRanks
AIM ImmunoTech Inc Provides Interim Update on DURIPANC Study - TradingView
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - GlobeNewswire
Pricey healthcare stocks with halting momentumlow momentum and high valuation (AIM:NYSE) - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):